Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-28T23:25:18.154Z Has data issue: false hasContentIssue false

A Strategy of “Combination Chemotherapy” in Alzheimer's Disease: Rationale and Preliminary Results with Physostigmine plus Deprenyl

Published online by Cambridge University Press:  07 January 2005

Trey Sunderland
Affiliation:
Section on Geriatric Psychiatry, National Institute of Mental Health, Bethesda, Maryland
Susan Molchan
Affiliation:
Section on Geriatric Psychiatry, National Institute of Mental Health, Bethesda, Maryland
Brian Lawlor
Affiliation:
Section on Geriatric Psychiatry, National Institute of Mental Health, Bethesda, Maryland Mt. Sinai School of Medicine, New York, New York, U.S.A.
Rick Martinez
Affiliation:
Section on Geriatric Psychiatry, National Institute of Mental Health, Bethesda, Maryland
Alan Mellow
Affiliation:
Section on Geriatric Psychiatry, National Institute of Mental Health, Bethesda, Maryland University of Michigan School of Medicine, Ann Arbor, Michigan, U.S.A.
Heidi Martinson
Affiliation:
Section on Geriatric Psychiatry, National Institute of Mental Health, Bethesda, Maryland
Karen Putnam
Affiliation:
Section on Geriatric Psychiatry, National Institute of Mental Health, Bethesda, Maryland
François Lalonde
Affiliation:
Section on Geriatric Psychiatry, National Institute of Mental Health, Bethesda, Maryland

Abstract

Although the central cholinergic deficits are still considered to be of primary importance in Alzheimer's disease, there is great need for an expansion of the pharmacological approach in this illness beyond the simple cholinergic replacement hypothesis. This report focuses on the concept of “combination chemotherapy” in Alzheimer's disease as the next generation of therapeutic strategies. Based on earlier positive findings in Alzheimer patients with the monoamine oxidase B inhibitor, 1-deprenyl, the authors speculate that a combination of physostigmine, the short-acting cholinesterase inhibitor, and 1-deprenyl might be more beneficial than either agent alone. The authors outline a sample paradigm for such combination studies, report preliminary data on the first 16 Alzheimer subjects to have received an initial combination of physostigmine and deprenyl, and point to other possible “combination chemotherapy” strategies for future study.

Type
Research Article
Copyright
© 1992 Springer Publishing Company

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)